Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Nyxoah S.A.NASDAQ: NYXH

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of €16M (cash outflow) fell 28.5% year over year, behind the +24.9% change in trailing-twelve-month net income. Sequentially, it fell 31.9% from the prior quarter. Over 3 fiscal years it compounded at +44.2% a year.

Context

  • Net income amounted to 898.7% of revenue in FY2025, down 349.5 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -€44.46M (-50.6%) for the fiscal year ending Dec 2026, a slowdown from the +59.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€16M-31.9% QoQ
Last fiscal yearDec 2025
-€90.05M+59.6% YoY
LTMMar 2026
-€83.7M+24.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.5%+116.2%+144.7 pp
1 year+59.6%-50.6%-110.2 pp
3-year CAGR+44.2%-44.5%-88.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the cash flow

Latest · FY2025
(90.05M) EUR
Year-over-year change
-59.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NYXH compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +24.9% is the 5th highest of 10, against a peer median of -11.4%.
  • Net income amounts to 512.9% of revenue for NYXH, versus a peer median of 60.5%.
NYXH Competitors
Net Income for NYXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$111.13M USD+30.5%+91.6%17982.7%
NYXHNyxoah S.A.LTM Mar 2026€83.7M EUR+24.9%+44.2%512.9%
IVVDInvivyd, Inc.LTM Mar 2026$77.6M USD-45.6%-39.9%138.9%
OSUROraSure Technologies, Inc.LTM Mar 2026$71.83M USD+124.8%-84.4%63.6%
PREPrenetics Global LimitedLTM Mar 2026$65.41M USD+35.9%-34.8%57.5%
TARAProtara Therapeutics, Inc.LTM Mar 2026$63.31M USD+39.4%-4.5%—
OABIOmniAb, Inc.LTM Mar 2026$54.29M USD-11.4%+42.6%187.8%
STIMNeuronetics, Inc.LTM Mar 2026$37.52M USD-22.7%+1.7%24.7%
UTMDUtah Medical Products, Inc.LTM Mar 2026$10.85M USD-16.3%-11.8%28.9%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$2.28M USD-57.0%-32.7%5.3%
Peer median (excluding NYXH) —-11.4%-11.8%60.5%

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.64M)(30.06M)(44.66M)(56.43M)(90.05M)
Depreciation & Amortization1.66M1.93M2.36M2.72M4.48M
Deferred Income Tax00000
Stock-Based Compensation1.27M2.7M2.61M3.97M0
Change in Working Capital(1.14M)86K(3.49M)2.96M5.37M
Accounts Receivables(2.52M)7K(1.54M)(751K)(2.14M)
Inventory(291K)(536K)(2.43M)(1.4M)55.98K
Accounts Payables00007.45M
Other Working Capital1.67M615K479K5.11M0
Other Non-Cash Items(2.49M)(3.42M)(1.6M)(2.44M)12.7M
Operating Cash Flow(25.34M)(28.76M)(44.78M)(49.23M)(67.5M)
Capital Expenditures(11.82M)(16.35M)(10.96M)(6.07M)(804.7K)
Acquisitions (Net)00003K
Purchases of Investments0(102.62M)(80.02M)(97.83M)(42.03M)
Sales of Investments028.91M120.68M85.31M71.97M
Other Investing Activities(10.35M)(15.35M)(6.15M)(2.64M)0
Investing Cash Flow(11.82M)(89.95M)32.01M(16.33M)26.17M
Debt Repayment(863K)(1.07M)(1.24M)8.48M21.19M
Common Stock Issued77.73M255K18.34M69.72M20.86M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(393K)(167K)(243K)(758K)(3.26M)
Financing Cash Flow76.47M(983K)16.86M77.44M38.79M
Effect of Forex Changes3.89M2.06M(369K)688K2.41M
Net Change in Cash43.21M(117.62M)3.72M12.58M(130.69K)
Free Cash Flow(37.15M)(45.11M)(55.74M)(55.3M)(68.3M)

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.